In NSCLC patients in China, the positive rate of EGFR mutation is 40%-50%, followed by KRAS (15%-30%), ALK (3%-7%), ROS1 (1%-2%), and RET protooncogene (RET) (1%-2%) [6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.